Citadel Advisors - KURA ONCOLOGY INC ownership

KURA ONCOLOGY INC's ticker is KURA and the CUSIP is 50127T109. A total of 105 filers reported holding KURA ONCOLOGY INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of KURA ONCOLOGY INC
ValueSharesWeighting
Q3 2023$13,557,719
-34.2%
1,486,592
-23.7%
0.00%
-25.0%
Q2 2023$20,612,115
-13.2%
1,948,215
+0.4%
0.00%
-20.0%
Q1 2023$23,742,185
+155.0%
1,941,307
+158.8%
0.01%
+150.0%
Q4 2022$9,310,726
+66.6%
750,260
+83.3%
0.00%
+100.0%
Q3 2022$5,590,000
+72.0%
409,266
+130.8%
0.00%0.0%
Q2 2022$3,250,000
-6.3%
177,334
-17.8%
0.00%0.0%
Q1 2022$3,467,000
-32.8%
215,633
-41.5%
0.00%0.0%
Q4 2021$5,163,000
+65.5%
368,750
+121.4%
0.00%0.0%
Q3 2021$3,120,000
+129.7%
166,558
+155.8%
0.00%
Q2 2021$1,358,000
-96.7%
65,105
-95.5%
0.00%
-100.0%
Q1 2021$41,278,000
-59.7%
1,460,117
-53.5%
0.01%
-61.5%
Q4 2020$102,498,000
+54.5%
3,138,313
+44.9%
0.03%
+36.8%
Q3 2020$66,354,000
+300.9%
2,165,586
+113.3%
0.02%
+216.7%
Q2 2020$16,552,000
+168.4%
1,015,382
+63.8%
0.01%
+100.0%
Q1 2020$6,168,000
+549.3%
619,954
+797.1%
0.00%
Q4 2019$950,000
+314.8%
69,105
+357.1%
0.00%
Q3 2019$229,000
-96.1%
15,118
-95.0%
0.00%
-100.0%
Q2 2019$5,940,000
+991.9%
301,686
+677.7%
0.00%
Q4 2018$544,000
+11.7%
38,792
+39.4%
0.00%
Q3 2018$487,000
+4.1%
27,831
+8.3%
0.00%
Q2 2018$468,00025,7080.00%
Other shareholders
KURA ONCOLOGY INC shareholders Q1 2019
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 1,849,947$16,871,5179.37%
Prosight Management, LP 1,932,456$17,623,9995.58%
ACUTA CAPITAL PARTNERS, LLC 702,093$6,403,0884.29%
ALETHEA CAPITAL MANAGEMENT, LLC 350,445$3,196,0583.93%
SUVRETTA CAPITAL MANAGEMENT, LLC 7,335,845$66,902,9063.62%
Affinity Asset Advisors, LLC 856,535$7,811,5992.20%
TCG Crossover Management, LLC 1,423,642$12,983,6151.91%
EcoR1 Capital, LLC 5,806,871$52,958,6641.79%
BVF INC/IL 6,730,983$61,386,5651.66%
DAFNA Capital Management LLC 550,784$5,023,1501.56%
View complete list of KURA ONCOLOGY INC shareholders